bioAffinity Technologies, Inc.

BIAF Nasdaq SEC CIK 1712762
Follow bioAffinity Technologies Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $1.1M −26% vs same quarter last year
Net income −$5.3M −4.5% vs same quarter last year
EPS, diluted −$5.89
Operating cash flow −$3.9M −56.1% vs same quarter last year
Revenue by quarter
$2.2M
$1.9M
$1.3M
$1.4M
$1.6M
$1.4M
$1.5M
$1.1M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
  • Revenue
  • Net income
−$20M−$10M$0$10MFY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$6.2M−$14.9M
FY24$9.4M−$9M
FY23$2.5M−$7.9M
FY22$4.8K−$8.2M
FY21-−$6.3M
FY20--
MarginsShare of revenue
  • Operating margin
  • Net margin
−200000%−150000%−100000%−50000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−171.6%−242%
FY24−95.6%−96.6%
FY23−314.8%−313.4%
FY22−83511.5%−169771.2%
FY21--
FY20--
Free cash flowOperating cash flow minus capital expenditure
−$10M−$7.5M−$5M−$2.5M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$9.4M
FY24−$7.3M
FY23−$6.1M
FY22−$4.3M
FY21-
FY20-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • bioAffinity Technologies
  • Healthcare median
−200000%−150000%−100000%−50000%0%FY20FY21FY22FY23FY24FY25
Show the numbers
YearbioAffinity TechnologiesHealthcare median
FY25−242%−30.6%
FY24−96.6%−47%
FY23−313.4%−58%
FY22−169771.2%−80.4%
FY21-−71.9%
FY20-−62.2%